Finch Therapeutics Group, Inc. FNCH
We take great care to ensure that the data presented and summarized in this overview for Finch Therapeutics Group, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in FNCH
Top Purchases
Top Sells
About FNCH
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Insider Transactions at FNCH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2024
|
Jeffery A Smisek |
SELL
Bona fide gift
|
Indirect |
383
-1.55%
|
-
|
|
Jun 07
2024
|
Jeffery A Smisek |
SELL
Bona fide gift
|
Direct |
384
-2.1%
|
-
|
|
May 20
2024
|
Jeffery A Smisek |
SELL
Bona fide gift
|
Indirect |
3,750
-100.0%
|
-
|
|
Mar 28
2024
|
Jeffery A Smisek |
SELL
Open market or private sale
|
Indirect |
1,600
-19.72%
|
$3,200
$2.61 P/Share
|
|
Mar 28
2024
|
Jeffery A Smisek |
SELL
Open market or private sale
|
Direct |
6,642
-100.0%
|
$13,284
$2.57 P/Share
|
|
Nov 22
2023
|
Jeffery A Smisek |
SELL
Open market or private sale
|
Direct |
1,470
-18.12%
|
$4,410
$3.64 P/Share
|
|
Jun 09
2023
|
Susan E Graf Director |
BUY
Open market or private purchase
|
Direct |
5,010
+50.0%
|
$0
$0.27 P/Share
|
|
Feb 21
2023
|
Marc Blaustein Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,619
-14.16%
|
$0
$0.38 P/Share
|
|
Oct 21
2022
|
Marc Blaustein Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,636
-10.03%
|
$3,636
$1.39 P/Share
|
|
Oct 21
2022
|
Joseph Vittiglio Chief Business & Legal Officer |
SELL
Open market or private sale
|
Direct |
3,636
-10.39%
|
$3,636
$1.39 P/Share
|
|
Jun 13
2022
|
Joseph Vittiglio Chief Business & Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+50.0%
|
-
|
|
Jun 13
2022
|
Marc Blaustein Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+49.12%
|
-
|
|
Dec 20
2021
|
Nicholas Haft Director |
BUY
Open market or private purchase
|
Indirect |
63,850
+1.55%
|
$638,500
$10.18 P/Share
|
|
Mar 23
2021
|
Crestovo Investor LLC Director |
BUY
Open market or private purchase
|
Direct |
735,294
+5.5%
|
$12,499,998
$17.0 P/Share
|
|
Mar 23
2021
|
Crestovo Investor LLC Director |
BUY
Conversion of derivative security
|
Direct |
11,906,147
+50.0%
|
-
|
|
Mar 23
2021
|
Domenic J Ferrante Director |
BUY
Open market or private purchase
|
Indirect |
102,941
+13.93%
|
$1,749,997
$17.0 P/Share
|
|
Mar 23
2021
|
Domenic J Ferrante Director |
BUY
Conversion of derivative security
|
Indirect |
533,254
+34.98%
|
-
|
|
Mar 23
2021
|
Nicholas Haft Director |
BUY
Open market or private purchase
|
Indirect |
882,351
+50.0%
|
$14,999,967
$17.0 P/Share
|
|
Mar 23
2021
|
Nicholas Haft Director |
BUY
Conversion of derivative security
|
Indirect |
3,110,706
+45.06%
|
-
|
|
Mar 23
2021
|
Jeffery A Smisek |
BUY
Open market or private purchase
|
Indirect |
88,235
+4.95%
|
$1,499,995
$17.0 P/Share
|
Last 12 Months Summary
| Bona fide gift | 4.52K shares |
|---|---|
| Open market or private sale | 9.71K shares |